Tumor-specific peptide epitopes that are generated from mutated genes and presented on cell surface MHC molecules, known as neoantigens, are attractive targets for therapeutic vaccination given the lack of central tolerance and corresponding presence of endogenous T cells that recognize them (Schumacher and Schreiber, 2015). The gene discussed is HLA-C; the disease is neoplasm.